ArticleOpen life sciences2025
Zinc valproic acid complex promotes osteoblast differentiation and exhibits anti-osteoporotic potential.
Article in Open life sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evaluating the risk of osteopenia-related adverse events with antiepileptic drugs: a pharmacovigilance study based on the FAERS database.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study explores the potential of zinc valproic acid (Z-VA) complex as a promoter of osteoblast differentiation and a preventive agent against osteoporosis. The concentration of 25 µM Z-VA improved osteoblast differentiation by increasing the expression of Runx2 and type 1 collagen mRNA, alkaline phosphatase activity, and cellular calcium deposition. Dexamethasone-induced osteoporosis models were used in zebrafish and rats. In the zebrafish scale regeneration model, Z-VA decreased the hydroxyproline content and tartrate-resistant acid phosphatase activity while also upregulating the calcium to phosphorus molar ratio, Runx2a MASNA isoform, collagen2α, osteocalcin, and osteonectin. Additionally, Z-VA upregulated osteopontin and mitogen-activated protein kinase expression and downregulated matrix metalloproteinase 3 expression. Z-VA increased calcium deposition, callus formation, and bone growth in a zebrafish fracture model. In the rat model, Z-VA increased the bone transverse diameter, length, weight, mineral content, and mineral density, as well as serum Ca
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.